Press releases
- Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress
- Bausch + Lomb INFUSE® for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States
- Bausch + Lomb Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States
- Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results
- Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry’s Meeting®
- Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens
- Bausch + Lomb Announces First-Quarter 2024 Results
- Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting
- Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
- Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs
More ▼
Key statistics
As of last trade, Bausch + Lomb Corp (S2L:DUS) traded at 13.70, 11.38% above the 52 week low of 12.30 set on May 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.90 |
---|---|
High | 13.90 |
Low | 13.70 |
Bid | 13.70 |
Offer | 14.10 |
Previous close | 13.80 |
Average volume | 8.25 |
---|---|
Shares outstanding | 351.83m |
Free float | 40.46m |
P/E (TTM) | -- |
Market cap | 5.31bn USD |
EPS (TTM) | -0.9603 USD |
Data delayed at least 15 minutes, as of Jun 17 2024 18:32 BST.
More ▼